Syndax Pharmaceuticals, Inc. (SNDX)
Summary
SNDX Chart
People also search for
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax Pharmaceuticals remains a "Strong Buy," driven by label expansion and robust revenue growth for Revuforj and Niktimvo. Company achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Niktimvo, already approved for cGVHD, is being advanced into IPF and 1st-line cGVHD, with key phase 2 data readouts expected in Q4 2026.
Syndax Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 113 | $2,639.6 | $1,512.13 | -$1,127.47 | -42.71% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 474 | $10,361.64 | $6,332.73 | -$4,028.91 | -38.88% |
| BG Bart Gancher Intech Investment Management LLC | 24,760 | $364,625.36 | $329,927 | -$34,698.36 | -9.52% |
| KM Kristin Mariani Janus Henderson Group PLC | 39,335 | $890,571.88 | $528,662.4 | -$361,909.48 | -40.64% |
| RAS Robert A. Saperstein Guggenheim Capital LLC | 16,056 | $244,750.22 | $217,237.68 | -$27,512.54 | -11.24% |
Syndax Pharmaceuticals, Inc. (SNDX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Syndax Pharmaceuticals, Inc. ever had a stock split?
Syndax Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael A. Metzger CEO | NASDAQ (NGS) Exchange | 87164F105 CUSIP |
| US Country | 298 Employees | - Last Dividend | - Last Split | 3 Mar 2016 IPO Date |
Overview
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical organization focused on the discovery and development of novel treatments for cancer. Established in 2005, the company is driven by a commitment to provide innovative therapies that address unmet medical needs in the oncology space. With its headquarters in Waltham, Massachusetts, Syndax Pharmaceuticals has positioned itself as a leader in the fight against cancer, leveraging cutting-edge science and research to develop transformative medicines. The firm’s dedication to advancing cancer treatment is evidenced by its robust pipeline of product candidates and partnerships aimed at enhancing the development and commercialization of its potential treatments. Through strategic collaborations and a deep understanding of cancer biology, Syndax is working to bring new hope to patients suffering from this devastating disease.
Products and Services
- Revumenib
Revumenib stands out as Syndax Pharmaceuticals' leading product candidate, configured as a powerful and selective small molecule inhibitor targeting the menin-MLL binding interaction. It is primarily being developed for the treatment of KMT2A rearranged acute leukemias and solid tumors. Revumenib's mechanism of action disrupts critical protein interactions responsible for the growth of certain cancer cells, offering a novel approach to treating these malignancies.
- SNDX-6352/Axatilimab
Another pivotal product in Syndax's lineup is SNDX-6352, also known as axatilimab. This therapeutic is a monoclonal antibody designed to inhibit the colony stimulating factor 1 receptor (CSF-1R). Its primary indications are for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF), two conditions with significant unmet medical needs. By blocking CSF-1R, axatilimab may help modulate the immune response and alleviate the symptoms of these serious diseases.
- Entinostat
Beyond revumenib and axatilimab, Syndax is also advancing Entinostat, another flagship investigational compound. While specific details regarding its mechanism and targeted indications were not provided in the overview, Entinostat represents a crucial part of the company's diversified portfolio in oncology. Syndax has secured a licensing and development agreement with Eddingpharm International Company Limited, aimed at bolstering the commercialization prospects of Entinostat, indicating its potential significance in cancer treatment regimens.
Contact Information
